Current knowledge on MDMA-assisted therapy for treating posttraumatic stress disorder

MDMA-assisted psychotherapy (MDMA-AT) has shown promising outcomes in recent randomized controlled trials with high response and remission rates.

• The U.S. Food and Drug Administration declined to approve MDMA-AT for marketable use due to concerns about insufficient evidence.
• Current literature review indicates a need to address limitations in previous studies, including challenges with blinding and safety monitoring.
• Gaps in evidence include the absence of active comparator conditions and head-to-head comparisons of different treatment models.
• Emerging research is integrating MDMA with established trauma-focused therapies to enhance treatment effectiveness.
• Future research directions focus on advancing knowledge and considerations for the dissemination of MDMA-AT.

Simplified